Dr. Yixin Zhou 周溢鑫
Chief Physician
Department of Comprehensive Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Personalized comprehensive treatment for lung cancer, liver cancer, gastrointestinal tumors, and neuroendocrine tumors using immunotherapy, chemotherapy, and targeted therapy.
Dr. Zhou holds a PhD and is a Chief Physician and Master’s Supervisor at Sun Yat-sen University Cancer Center. Dr. Zhou graduated from the eight-year clinical medicine program at Sun Yat-sen University. Clinical work focuses on personalized comprehensive treatment for solid tumors, including lung and digestive system cancers. Dr. Zhou serves as a reviewer for journals such as Lung Cancer.
Professional roles
- Vice Chair, Immunotherapy Branch, Guangdong Health Care Association
- Member, Tumor Emergency and Critical Care Committee, Guangdong Chest Disease Society
- Member, Brain Metastasis Professional Committee, Guangdong Chest Tumor Prevention and Treatment Research Association
- Standing Committee Member, Public Nutrition Society, Guangdong Nutrition Society
Name order: in Chinese the family name comes first (Zhou Yixin). Papers usually list the name as Yixin Zhou or Zhou Y.
Selected publications
58 papers on PubMed matched by name and affiliation; 13 as first or senior author since 2016. Most recent first- or senior-author papers:
- Clin Transl Oncol, 2026 (senior author): Zolbetuximab plus chemotherapy versus immune checkpoint inhibitor plus chemotherapy as first-line treatment for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: an anchored indirect meta-analysis. PubMed 42932139
- Curr Oncol, 2026 (senior author): Comparative Efficacy and Safety of First-Line Immune Checkpoint Inhibitors Plus Chemotherapy with or Without Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Carcinoma. PubMed 41892201
- Front Pharmacol, 2025 (senior author): Comparative analysis of first-generation epidermal growth factor receptor inhibitors combined with chemotherapy versus third-generation epidermal growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis. PubMed 40894225
- Chin Med J (Engl), 2025 (senior author): Efficacy and safety of immune checkpoint inhibitors in the treatment of recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis. PubMed 39602325
- Eur J Cancer, 2024 (first author): Placebo immune-related adverse events (irAEs): A neglected phenomenon in cancer immunotherapy trials. PubMed 38981314
- JAMA Netw Open, 2024 (first author): Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis. PubMed 38451524
- Ann Transl Med, 2021 (senior author): Assessment of sarcopenia as a predictor of poor overall survival for advanced non-small-cell lung cancer patients receiving salvage anti-PD-1 immunotherapy. PubMed 35071495
- Front Oncol, 2021 (first author): Comparison of PD-1 Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma in the Second-Line Setting. PubMed 34621668
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion